SI20070A - Nove soli inhibitorjev HMG-CoA reduktaze - Google Patents

Nove soli inhibitorjev HMG-CoA reduktaze Download PDF

Info

Publication number
SI20070A
SI20070A SI9800240A SI9800240A SI20070A SI 20070 A SI20070 A SI 20070A SI 9800240 A SI9800240 A SI 9800240A SI 9800240 A SI9800240 A SI 9800240A SI 20070 A SI20070 A SI 20070A
Authority
SI
Slovenia
Prior art keywords
hmg
coa reductase
alkyl
salts
group
Prior art date
Application number
SI9800240A
Other languages
English (en)
Slovenian (sl)
Inventor
Zlatko Pflaum
Original Assignee
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. filed Critical LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.
Priority to SI9800240A priority Critical patent/SI20070A/sl
Priority to AT99941798T priority patent/ATE271026T1/de
Priority to AU55285/99A priority patent/AU765373C/en
Priority to DE69918697T priority patent/DE69918697T2/de
Priority to KR1020017000758A priority patent/KR100699368B1/ko
Priority to NZ509583A priority patent/NZ509583A/en
Priority to HU0103007A priority patent/HUP0103007A3/hu
Priority to PCT/IB1999/001554 priority patent/WO2000017150A1/en
Priority to EP99941798A priority patent/EP1114021B1/de
Priority to CA002343646A priority patent/CA2343646A1/en
Priority to SI9930627T priority patent/SI1114021T1/xx
Priority to IL14205599A priority patent/IL142055A/en
Priority to EP04011699A priority patent/EP1466886A3/de
Priority to JP2000574060A priority patent/JP3834203B2/ja
Priority to US09/787,387 priority patent/US6583295B1/en
Priority to CNB998110736A priority patent/CN1228304C/zh
Publication of SI20070A publication Critical patent/SI20070A/sl
Priority to IS5891A priority patent/IS2113B/is
Priority to US10/320,285 priority patent/US6838566B2/en
Priority to US10/966,000 priority patent/US20050049422A1/en
Priority to US11/901,634 priority patent/US20080188552A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/09—Diamines
    • C07C211/10—Diaminoethanes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/03—Monoamines
    • C07C211/07—Monoamines containing one, two or three alkyl groups, each having the same number of carbon atoms in excess of three
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/09—Diamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/14—Amines containing amino groups bound to at least two aminoalkyl groups, e.g. diethylenetriamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI9800240A 1998-09-18 1998-09-18 Nove soli inhibitorjev HMG-CoA reduktaze SI20070A (sl)

Priority Applications (20)

Application Number Priority Date Filing Date Title
SI9800240A SI20070A (sl) 1998-09-18 1998-09-18 Nove soli inhibitorjev HMG-CoA reduktaze
CA002343646A CA2343646A1 (en) 1998-09-18 1999-09-17 New salts of hmg-coa reductase inhibitors
SI9930627T SI1114021T1 (en) 1998-09-18 1999-09-17 NEW SALTS OF HMG-CoA REDUCTASE INHIBITORS
DE69918697T DE69918697T2 (de) 1998-09-18 1999-09-17 Neue sälze von hmg-coa reductase inhibitoren
KR1020017000758A KR100699368B1 (ko) 1998-09-18 1999-09-17 신규한 ＨＭＧ-ＣｏＡ 환원효소 억제제 염
NZ509583A NZ509583A (en) 1998-09-18 1999-09-17 Amine salts of HMG-CoA reductase inhibitors used to purify HMG-CoA reductase inhibitors
HU0103007A HUP0103007A3 (en) 1998-09-18 1999-09-17 New salts of hmg-coa reductase inhibitors and process for their preparation
PCT/IB1999/001554 WO2000017150A1 (en) 1998-09-18 1999-09-17 NEW SALTS OF HMG-CoA REDUCTASE INHIBITORS
EP99941798A EP1114021B1 (de) 1998-09-18 1999-09-17 Neue sälze von hmg-coa reductase inhibitoren
AT99941798T ATE271026T1 (de) 1998-09-18 1999-09-17 Neue sälze von hmg-coa reductase inhibitoren
AU55285/99A AU765373C (en) 1998-09-18 1999-09-17 New salts of HMG-CoA reductase inhibitors
IL14205599A IL142055A (en) 1998-09-18 1999-09-17 SALTS OF HMG-CoA REDUCTASE INHIBITORS AND THEIR PREPARATION
EP04011699A EP1466886A3 (de) 1998-09-18 1999-09-17 Neue Salze von HMG-CoA Reductase-inhibitoren
JP2000574060A JP3834203B2 (ja) 1998-09-18 1999-09-17 新規のＨＭＧ−ＣｏＡレダクターゼインヒビターの塩
US09/787,387 US6583295B1 (en) 1998-09-18 1999-09-17 Salts of HMG-CoA reductase inhibitors
CNB998110736A CN1228304C (zh) 1998-09-18 1999-09-17 新的HMG－CoA还原酶抑制剂盐
IS5891A IS2113B (is) 1998-09-18 2001-03-15 Ný sölt HMG-CoA redúktasatálma
US10/320,285 US6838566B2 (en) 1998-09-18 2002-12-16 Salts of HMG-CoA reductase inhibitors
US10/966,000 US20050049422A1 (en) 1998-09-18 2004-10-15 New salts of HMG-CoA reductase inhibitors
US11/901,634 US20080188552A1 (en) 1998-09-18 2007-09-18 New salts of HMG-CoA reductase inhibitors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SI9800240A SI20070A (sl) 1998-09-18 1998-09-18 Nove soli inhibitorjev HMG-CoA reduktaze

Publications (1)

Publication Number Publication Date
SI20070A true SI20070A (sl) 2000-04-30

Family

ID=20432331

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9800240A SI20070A (sl) 1998-09-18 1998-09-18 Nove soli inhibitorjev HMG-CoA reduktaze

Country Status (15)

Country Link
US (4) US6583295B1 (de)
EP (2) EP1466886A3 (de)
JP (1) JP3834203B2 (de)
KR (1) KR100699368B1 (de)
CN (1) CN1228304C (de)
AT (1) ATE271026T1 (de)
AU (1) AU765373C (de)
CA (1) CA2343646A1 (de)
DE (1) DE69918697T2 (de)
HU (1) HUP0103007A3 (de)
IL (1) IL142055A (de)
IS (1) IS2113B (de)
NZ (1) NZ509583A (de)
SI (1) SI20070A (de)
WO (1) WO2000017150A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0251582A (ja) * 1988-08-12 1990-02-21 Kyokado Eng Co Ltd 地盤注入用薬液
AU782143B2 (en) * 1998-09-18 2005-07-07 Lek Pharmaceuticals D.D. Crystals of the sodium salt of pravastatin
SI20305A (sl) * 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
EP1491522A1 (de) * 1999-02-03 2004-12-29 Institute for Drug Research Ltd. Mikrobielles Verfahren zur Herstellung von Pravastatin
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
WO2001093860A1 (en) 2000-06-09 2001-12-13 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
US6806290B2 (en) 2000-06-09 2004-10-19 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
IL155194A0 (en) * 2000-10-05 2003-11-23 Biogal Pharmaceutical Co Ltd Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
JP2002121172A (ja) * 2000-10-16 2002-04-23 Sankyo Co Ltd プラバスタチン又はその薬理上許容される塩の精製方法
NL1017548C2 (nl) 2001-03-09 2002-09-10 Synthon Bv Een lactonisatie proces.
EP1404301A4 (de) * 2001-06-21 2006-03-22 Andrx Pharmaceuticals Inc Pravastatin enthaltende stabile pharmazeutische zusammensetzungen mit kontrollierter freisetzung
JP2003026634A (ja) * 2001-07-17 2003-01-29 Mercian Corp プラバスタチンナトリウム塩の製造方法
JP2003093045A (ja) * 2001-09-26 2003-04-02 Godo Shusei Co Ltd 有用変換微生物
CA2486557A1 (en) * 2002-06-13 2003-12-24 Novartis Ag Calcium salts of indole derived statins
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
WO2005014541A1 (en) * 2003-08-12 2005-02-17 Biocon Limited Novel antihypercholesterolemic compound
CA2537271A1 (en) 2003-08-28 2005-03-17 Teva Pharmaceutical Industries, Ltd. Process for preparation of rosuvastatin calcium
US20070276027A1 (en) 2003-09-17 2007-11-29 Warner-Lambert Company Llc Crystalline Forms of [R-(R* ,R*)]-2-(4-Fluorophenyl)-Beta, -Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Carbonyl]-1H-Pyrrole-1-Heptanoic Acid
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
TW200526596A (en) * 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
EP1689723B1 (de) 2003-12-02 2011-04-27 Teva Pharmaceutical Industries, Ltd. Referenzstandard zur charakterisierung von rosuvastatin
EP1709008A1 (de) * 2004-01-19 2006-10-11 Ranbaxy Laboratories Limited Salze von hmg-coa-reduktase-inhibitoren und deren verwendung
US8158362B2 (en) * 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
US7875731B2 (en) 2004-05-05 2011-01-25 Pfizer Inc. Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid
US7179916B2 (en) 2004-07-13 2007-02-20 Teva Pharmaceutical Industries Ltd. Process for the preparation of rosuvastatin
US7642287B2 (en) * 2004-08-06 2010-01-05 Transform Pharmaceuticals, Inc. Statin pharmaceutical compositions and related methods of treatment
JP2008516890A (ja) * 2004-08-06 2008-05-22 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 新規なフェノフィブラート製剤および関連治療方法
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
WO2006072963A1 (en) * 2005-01-10 2006-07-13 Concord Biotech Limited Process for preparing simvastatin from lovastatin amine salts in three steps
TWI353981B (en) 2005-02-22 2011-12-11 Teva Pharma Preparation of rosuvastatin
CA2499047A1 (en) * 2005-03-01 2006-09-01 Apotex Pharmachem Inc. Process for producing atorvastatin hemicalcium
JP4813841B2 (ja) * 2005-07-25 2011-11-09 キユーピー株式会社 プラバスタチンナトリウムの製造方法
EP1805148A2 (de) 2005-08-16 2007-07-11 Teva Pharmaceutical Industries Ltd. Kristallines rosuvastatinzwischenprodukt
PL211815B1 (pl) * 2007-11-19 2012-06-29 Inst Chemii Organicznej Polska Akademia Nauk Enzym esteraza lowastatyny osadzony na nośniku nierozpuszczalnym w wodzie, sposób osadzania enzymu, zastosowanie enzymu esterazy lowastatyny osadzonego na nosniku nierozpuszczalnym w wodzie, przepływowy reaktor biokatalityczny ze złożem oraz sposób wytwarzania i/lub oczyszczania symwastatyny
WO2009078033A2 (en) * 2007-12-18 2009-06-25 Themis Medicare Limited Isolation and recovery of simvastatin in lactone form or in the form of an acid salt from the harvested fermentation broth
WO2011089559A1 (en) * 2010-01-22 2011-07-28 Orchid Chemicals And Pharmaceuticals Limited A novel polymorphic form of atorvastatin salts
WO2012063115A2 (en) 2010-11-11 2012-05-18 Jubilant Life Sciences Ltd. Process for the preparation of rosuvastatin calcium via novel amine intermediate
CN114031496B (zh) * 2021-11-30 2024-09-27 广东蓝宝制药有限公司 一种高纯度普伐他汀1,1,3,3-四甲基丁胺的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4319039A (en) 1979-06-15 1982-03-09 Merck & Co., Inc. Preparation of ammonium salt of hypocholesteremic fermentation product
ES8105781A1 (es) 1979-07-27 1981-06-16 Sankyo Co Un procedimiento para la preparacion de sales y esteres, de monacolina k utiles como agentes antitlipercolesteremicos.
US4342767A (en) 1980-01-23 1982-08-03 Merck & Co., Inc. Hypocholesteremic fermentation products
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
JPS57123140A (en) 1981-01-23 1982-07-31 Sankyo Co Ltd Ml-236b carboxylic acid amine salt and remedy for hyperlipemia containing said salt as active component
JPS57185275A (en) 1981-05-07 1982-11-15 Sankyo Co Ltd Tetrahydro-dum-4 and tetrahydro-isodum-4 and their derivatives
US4997848A (en) * 1987-10-27 1991-03-05 Sankyo Company, Limited Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition
US5089523A (en) * 1990-05-11 1992-02-18 E. R. Squibb & Sons, Inc. Fluorinated derivatives of mevinic acids
US5223415A (en) * 1990-10-15 1993-06-29 Merck & Co., Inc. Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid)
HU217629B (hu) 1991-12-12 2000-03-28 Novartis Ag. Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására
HU221849B1 (hu) 1991-12-12 2003-02-28 Novartis Ag. HMG-CoA reduktáz inhibitor fluvasztatint tartalmazó stabilizált gyógyszerkészítmények
US5763653A (en) 1997-03-13 1998-06-09 Ranbaxy Laboratories, Ltd. Key intermediates in the manufacture of simvastatin
US5763646A (en) 1997-03-13 1998-06-09 Ranbaxy Laboratories, Ltd. Process for manufacturing simvastatin from lovastatin or mevinolinic acid
SI20305A (sl) * 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina

Also Published As

Publication number Publication date
HUP0103007A2 (hu) 2002-05-29
HUP0103007A3 (en) 2003-10-28
US6583295B1 (en) 2003-06-24
AU765373B2 (en) 2003-09-18
DE69918697T2 (de) 2005-07-28
EP1114021B1 (de) 2004-07-14
EP1114021A1 (de) 2001-07-11
AU5528599A (en) 2000-04-10
US6838566B2 (en) 2005-01-04
EP1466886A3 (de) 2009-02-25
JP2002526467A (ja) 2002-08-20
IL142055A0 (en) 2002-03-10
US20030120086A1 (en) 2003-06-26
EP1466886A2 (de) 2004-10-13
IS2113B (is) 2006-06-15
CA2343646A1 (en) 2000-03-30
JP3834203B2 (ja) 2006-10-18
US20050049422A1 (en) 2005-03-03
AU765373C (en) 2005-05-26
WO2000017150A1 (en) 2000-03-30
CN1228304C (zh) 2005-11-23
KR100699368B1 (ko) 2007-03-27
US20080188552A1 (en) 2008-08-07
IL142055A (en) 2004-06-20
DE69918697D1 (de) 2004-08-19
ATE271026T1 (de) 2004-07-15
CN1318046A (zh) 2001-10-17
NZ509583A (en) 2003-10-31
IS5891A (is) 2001-03-15
KR20010071959A (ko) 2001-07-31

Similar Documents

Publication Publication Date Title
SI20070A (sl) Nove soli inhibitorjev HMG-CoA reduktaze
AU655718B2 (en) Novel alkylenediammonium diclavulanate derivatives, a process for the preparation thereof as well as the use thereof
CS202194A3 (cs) Ochranné zařízení ráfku pro řetězy na pneumatiky, jakož i řetěz na pneumatiky s takovýmto ochranným zařízením ráfku
US6268186B1 (en) HMG-CoA reductase inhibitor preparation process
EP0175312B1 (de) Verfahren zur Herstellung von optisch aktiven Hydantoinen
EP0005614B1 (de) Lithium pseudomonat, Verfahren zu seiner Isolierung und seine Hydrolyse
SI9300556A (en) Method for the purification of clavulanic acid
SI9500134A1 (en) Preparation procedure of pure alkali salts of clavulanic acid
SI9500074A (en) Process for preparation of alkani salts of clavulanic acid.
Yazawa et al. A new formylation reagent: 4-formyl-2-methyl-1, 3, 4-thiadiazolin-5-thione.
US20110028712A1 (en) Diamine salts of carboxylic acids
RU2179171C2 (ru) Способ получения соли клавулановой кислоты
EP3717452A1 (de) Verfahren zur herstellung von acylierten amphetaminderivaten
NZ519434A (en) Process for the preparation of sodium salts of statins
EP0437567A1 (de) Phenylglycinderivate.
IES65748B2 (en) Process for the separation of the optical antipodes of racemic phenyl-(2-Pyridyl)-dimethylpropylamines

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20060817